Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

61.19
+0.52000.86%
Post-market: 61.190.00000.00%17:17 EST
Volume:802.48K
Turnover:49.23M
Market Cap:2.84B
PE:16.76
High:62.00
Open:60.90
Low:60.25
Close:60.67
52wk High:87.32
52wk Low:47.32
Shares:46.47M
Float Shares:46.47M
Volume Ratio:0.96
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.65
EPS(LYR):3.31
ROE:19.30%
ROA:6.45%
PB:3.12
PE(LYR):18.49

Loading ...

Haemonetics CEO Chris Simon Joins Raymond James Institutional Investors Conference Fireside Chat

Reuters
·
Yesterday

Haemonetics (HAE) Gets a Buy from BTIG

TIPRANKS
·
Yesterday

Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell?

Simply Wall St.
·
Feb 13

Haemonetics Corporation Releases 2024-2025 Corporate Responsibility Report

Reuters
·
Feb 13

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

GlobeNewswire
·
Feb 11

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

GlobeNewswire
·
Feb 10

Haemonetics Earnings Call: Strong Core, IVT Drag

TIPRANKS
·
Feb 08

These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Benzinga
·
Feb 07

Stock Track | Haemonetics Plummets 5.04% Intraday Following Series of Analyst Price Target Cuts

Stock Track
·
Feb 06

Haemonetics price target lowered to $81 from $99 at Baird

TIPRANKS
·
Feb 06

Haemonetics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Feb 06

Haemonetics price target lowered to $75 from $88 at Citi

TIPRANKS
·
Feb 06

Haemonetics Price Target Maintained With a $88.00/Share by BTIG

Dow Jones
·
Feb 06

Orchestra Biomed Unveils Vision for Growth With Updates on Pivotal Cardiovascular Trials and Strategic Partnerships

Reuters
·
Feb 06

Earnings Flash (HAE) Haemonetics Posts Fiscal Q3 Adjusted EPS $1.31, vs. FactSet Est of $1.22

MT Newswires Live
·
Feb 05

Haemonetics Outlook FY Organic Growth 0-2%

THOMSON REUTERS
·
Feb 05

Haemonetics Q3 Adjusted EPS USD 1.31 VS. Ibes Estimate USD 1.25

THOMSON REUTERS
·
Feb 05

GUIDANCE:(HAE) Haemonetics Expects Fiscal 2026 Adjusted EPS Range $4.90 - $5, vs. FactSet Est of $4.70

MT Newswires Live
·
Feb 05

Haemonetics Q3 Adj. EPS $1.31 Beats $1.25 Estimate, Sales $338.967M Beat $331.616M Estimate

Benzinga
·
Feb 05

Haemonetics posts Q3 adjusted earnings per share of USD 1.31, up 10%

Reuters
·
Feb 05